<DOC>
	<DOCNO>NCT00122044</DOCNO>
	<brief_summary>This study open-label trial trihexyphenidyl child upper extremity dystonia due cerebral palsy . It hypothesize trihexyphenidyl dos 0.75mg/kg/day would well-tolerated show significant change Melbourne scale upper extremity function .</brief_summary>
	<brief_title>Childhood Hypertonia Central Origin : A Trial Anticholinergic Treatment Effects</brief_title>
	<detailed_description>BACKGROUND : Although trihexyphenidyl use treat primary secondary dystonia child , previous study investigate efficacy secondary dystonia . We describe result prospective , open-label , multi-center trial high-dose trihexyphenidyl child secondary dystonia arm due cerebral palsy . METHODS : Twenty-six child age 4-15 year cerebral palsy dystonia impair function dominant upper extremity enrol . All child give trihexyphenidyl increase dos 9 week 0.75mg/kg/day . Trihexyphenidyl subsequently taper 5 week . Visits occur baseline , 9 week , 15 week . The primary outcome measure Melbourne assessment upper extremity function , test dominant arm . RESULTS : Three child withdraw due non-serious adverse event ( chorea , drug rash , hyperactivity ) . 3 child reduce dosage due non-serious adverse event . The 23 child complete study show significant improvement arm function 15 week ( p=0.045 ) 9 week . Post-hoc analysis show subgroup ( N=10 ) hyperkinetic dystonia worsen 9 week ( p=0.04 ) subsequently return baseline follow taper medicine . CONCLUSIONS : Trihexyphenidyl appear safe effective treatment arm dystonia child cerebral palsy . Children hyperkinetic dystonia may worsen . A large randomize prospective trial need confirm result .</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Trihexyphenidyl</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Dystonia dominant upper extremity Complete absence voluntary movement affect hand , wrist , elbow Severe weakness dominant upper extremity ( MRC grade &lt; 4 ) Passive range motion hand , wrist elbow le 80 % normal Current use medication dystonia ( anticholinergic , Ldopa , baclofen , diazepam , tizanidine , tetrabenazine , reserpine , others ) Changes subject 's physical therapy regimen duration 15week study Prior use trihexyphenidyl anticholinergic therapy dystonia . History surgery dominant upper extremity cervical spine Botulinum toxin injection dominant upper extremity within previous 6 month Current prior implantation intrathecal baclofen pump , deep brain stimulator , device treat dystonia spasticity Concurrent acute chronic medical condition ( frequent seizure , heart disease , asthma ) could adversely affect motor performance safety test Presence diurnal fluctuation clinical sign symptom suggest inborn error metabolism , family history dystonia suggest genetic dystonia , dystonia due injury neonatal period ( include toxin exposure , trauma , medicationinduced ) History allergic adverse reaction trihexyphenidyl anticholinergic medication Current complaint urinary retention require treatment . History glaucoma , family history glaucoma onset age 40</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>childhood</keyword>
	<keyword>cerebral palsy</keyword>
	<keyword>dystonia</keyword>
	<keyword>secondary</keyword>
	<keyword>trihexyphenidyl</keyword>
	<keyword>pediatric dystonia</keyword>
</DOC>